Search Results
Your search for Blood matches 4772 pages
Showing 51 - 100Kidney Cancer Cases Expected to Double by 2050
Projected cases of kidney cancer are expected to double by 2050 due to modifiable risk factors, according to findings and estimations published in European Urology. “Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for this steep rise,” stated ...
Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease
A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone. The phase II LUNAR trial is the...
Impact of Novel Donor Search Strategy on Outcomes for Potential HCT Recipients
In a study (BMT CTN 1702) reported in the Journal of Clinical Oncology, Lee et al found little difference in 2-year survival outcomes between patients considered “very likely” vs “very unlikely” to find an HLA-matched unrelated donor (MUD) for allogeneic hematopoietic cell transplantation as...
Cancer Deaths Expected to Rise to Over 18 Million in 2050
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new...
Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease
The U.S. Food and Drug Administration (FDA) has approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression after at least one line of...
Clonal Hematopoiesis
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, focuses on clonal hematopoiesis of indeterminate potential (also referred to as CHIP) as well as...
More Tattoos, Lower Risk of Melanoma? New Study Investigates
People with more than one tattoo session may have a decreased risk of developing melanoma—with one key caveat, according to research published by McCarty et al in the Journal of the National Cancer Institute. A team led by Jennifer Doherty, PhD, Huntsman Cancer Institute investigator, Co-Leader of ...
AACR Cancer Progress Report 2025 Highlights Breakthroughs in Blood Cancers and How NIH Funding Uncertainty Threatens Advances
The 15th edition of the annual AACR Cancer Progress Report presents a mixed picture of the major advances in cancer care over the past year, including the approval of 20 new anticancer drugs, juxtaposed against the continuing rise in early-onset cancers and disparities in care as well as the...
Osimertinib Plus Chemotherapy Significantly Prolongs Overall Survival in EGFR-Mutated Advanced NSCLC
The combination of the EGFR-targeting tyrosine kinase inhibitor osimertinib with platinum-based chemotherapy significantly improved overall survival as a first-line treatment for patients with EGFR-mutated, advanced, non–small cell lung cancer (NSCLC) compared with osimertinib monotherapy,...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be well tolerated, including in those with a longer duration of treatment and higher doses. Clinical...
Study Finds Insufficient Evidence Demonstrating Clinical Benefit of Multicancer Detection Tests
The U.S. Preventive Services Task Force currently recommends average-risk screening for four cancer types, including colorectal, cervical, breast, and lung cancer (for those with a sufficient smoking history). Despite this, approximately 70% of cancer-related deaths in the United States are due to...
New Liquid Biopsy Test for Early Detection of Head and Neck Cancers
According to the American Cancer Society (ACS), human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) is the most common type of HPV-related malignancy in the United States. In 2025, ACS estimates there will be 59,660 diagnoses of mouth and throat cancers, and about...
Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies
Many patients from Europe and the United States have experienced the benefits of anthracyclines in the treatment of an array of cancers, including solid tumors such as breast and ovarian cancers as well as lymphoma. However, a number of these cancer survivors will experience severe chronic cardiac...
DLL3-Targeted Antibody-Drug Conjugate in Relapsed SCLC
A first-in-human phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, demonstrated manageable safety and early signs of antitumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented at the International...
The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma
The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...
Do the Results From CARTITUDE-1 Represent a Cure for Patients With Multiple Myeloma? We Need Longer Follow-Up to Know for Sure
The results of the CARTITUDE-1 clinical trial demonstrate outstanding and unprecedented long-term efficacy with ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory multiple myeloma.1 (See the July 2025 issue of The ...
Aumolertinib Plus Chemotherapy Improves PFS in NSCLC With EGFR and Concomitant Tumor Suppressor Genes
New results from the phase III ACROSS 2 trial demonstrated that aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), combined with platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib monotherapy in patients with...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
PARP Inhibition Plus Abiraterone Shows Benefit in HRR-Altered Metastatic Castration-Sensitive Prostate Cancer
Use of the PARP inhibitor niraparib in combination with the androgen biosynthesis inhibitor abiraterone acetate and the corticosteroid prednisone reduced the risk of disease progression, both radiographic and symptomatic, in patients with metastatic castration-sensitive prostate cancer harboring...
Can a Common Anti-inflammatory Drug Help to Control Progression of Clonal Hematopoiesis?
Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published by Mohammadnia et al in JACC ...
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
IDO1 Inhibition Mitigates Diet-Induced Risk of Cancer-Associated VTE in Preclinical Models
Patients with cancer who have a diet high in tryptophan, or protein-rich foods, have an increased risk for developing cancer-associated venous thromboembolism, according to preclinical findings published in Blood Advances. This increased risk could potentially be mitigated by treatment with an...
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...
Lu-177 Dotatate in Progressive Metastatic Pheochromocytomas and Paragangliomas
In an interim analysis of a National Institutes of Health phase II study reported in the Journal of Clinical Oncology, Lin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) was active in progressive metastatic pheochromocytomas and paragangliomas (PPGLs). As stated by the investigators,...
Case 1: Management of Cardiovascular Risk Factors
This is Part 1 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss cardiovascular ...
Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows
In a case presentation published in The New England Journal of Medicine, targeted treatment was successful for chimeric antigen receptor (CAR)-positive peripheral T-cell lymphoma developed after CAR T-cell therapy for multiple myeloma. Using advanced genomic, phenotypic, and functional profiling...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Case 3: Patient With Myelofibrosis on Active Treatment
This is Part 3 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
Case 2: Patient With Myelofibrosis and Anemia
This is Part 2 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
Case 1: Patient With Newly Diagnosed Post-PV Myelofibrosis
This is Part 1 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of...
ASH Announces 2025 Hematologists to Be Honored With Top Awards and Distinguished Lectures
The American Society of Hematology (ASH) will recognize 11 hematologists who have made significant contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, on December 6–9. Rainer Storb, MD, of Fred...
OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight
Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally. It is the largest single donation ever made to a ...
John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director
John C. Byrd, MD, FASCO, an internationally lauded researcher and clinical specialist in hematologic malignancies, has been appointed Director of UPMC Hillman Cancer Center, effective November 2025. In his role as Director, Dr. Byrd will be responsible for all aspects of the University of...
Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers
For patients with gastrointestinal (GI) cancers, chemotherapy can sometimes cause severe, even life-threatening side effects in those who carry certain genetic variants that may impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting...
Novel Single-Cell Sequencing Blood Test for Multiple Myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that may alter the diagnosis and monitoring of multiple myeloma and its precursor conditions. The new method, known as SWIFT-seq, uses single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a...
Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS
Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...
Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years
It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...
Immunoglobulin Replacement Therapy and Infection Risks in CLL
Immunoglobulin replacement therapy did not lead to a reduction in the risk for serious infections leading to hospitalizations for patients with chronic lymphocytic leukemia (CLL), according to the results of a real-world Australian cohort study published in Blood Advances. This finding is at odds...
Pediatric Gliomas: Early Research on Targeted Therapies
A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common type of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and these gliomas may be sensitive to...
Immune Checkpoint Inhibitors, Cardiovascular Health, and a Potentially Protective Biomarker
New research out of Spain has shown that patients with cancer who had lower levels of the biomarker CD69 (receptor on T cells) before starting treatment with immune checkpoint inhibitors (ICIs) had a more negative immune response and were at higher risk of cardiovascular damage and myocarditis.1...
LLS Unveils Name Change
The Leukemia & Lymphoma Society (LLS), the global nonprofit in funding blood cancer research, patient support, and advocacy, is becoming Blood Cancer United on August 28, in advance of Blood Cancer Awareness Month in September. For more than 75 years, LLS has been committed to reaching and...
Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the impact of the prognostic marker RUNX1::RUX1T1 fusion on the diagnosis and treatment of...
Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC
In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...
Surviving Pancreatic Cancer
I’ve been blessed to have remained healthy for most of my life. In fact, I can’t remember ever spending a night in the hospital until I was diagnosed with pancreatic cancer, at age 86, in the summer of 2024. And even then, the symptoms that drove me to seek care in the emergency room of my local...
Updates in Systemic Light-Chain Amyloidosis
Systemic amyloid light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chains, produced by clonal CD38-positive plasma cells, as insoluble amyloid fibrils in vital organs. It is a disease that can progress rapidly and is fatal without treatment. The past decade...
Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice
The 2025 ASCO Annual Meeting included the presentation of data from more than 7,000 abstracts and clinical trials set to advance research, uncover findings, and in some cases change the standard of practice across multiple tumor types, moving science forward and improving care for the more than 2...
NSCLC Trial Shows Radiation May Overcome Primary Resistance to Pembrolizumab
The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in...
HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer
In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with early-stage, HER2-positive breast cancer. Study Details Systematic review of the literature...
Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer. Study Details In the multicenter, open-label ...
People With Acromegaly Face Elevated Cancer Risk, Study Finds
A new study presented at the 2025 Annual Meeting of the Endocrine Society (ENDO 2025) found that individuals with acromegaly—an endocrine disorder caused by excessive growth hormone secretion—are at a significantly heightened risk of developing various types of cancer, often at younger ages...
